AstraZeneca sees stock market value slump by more than £20bn after drug setback - The FTSE 100 firm found the Wainua drug ...

Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...

Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.

AstraZeneca loses £20 billion in value after disappointing trial results for a key heart disease drug. Find out more.

By Raechel Thankam Job July 9 (Reuters) - AstraZeneca's nerve disease drug Wainua, made in partnership with Ionis, ...

Heavy falls in AstraZeneca saw London’s FTSE 100 underperform European peers, while investors continue to weigh up ...

Astra's shares tumbled 10.5% after it said its Wainua drug - which it is developing with Ionis - failed to reduce deaths ...

Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation July 6, 2026 9:30 AM ...

AstraZeneca shares tumbled nearly 10% in London after a late-stage trial for an experimental heart disease failed to meet its ...

July 8 (Reuters) - Drugmakers AstraZeneca and Daiichi Sankyo are nearing an agreement with the UK's pricing regulator for ...

AstraZeneca reports 88% emissions cut since 2015, crediting AI for accelerating drug discovery while embedding sustainability ...